MoneyWorks4Me

Shilpa Medicare informs about company updates

25 Apr 2022 Evaluate

Shilpa Medicare has informed that the Company, via its wholly owned subsidiary, Shilpa Biologicals (SBPL), has received a NoC from RCGM, Dept of Biotechnology to approach the DCGI to conduct Clinical studies for its Biosimilar Aflibercept - a first from an Indian company. The product is a biosimilar version of EYLEA of Regeneron for which currently there is no other biosimilar version on the Indian market.

The above information is a part of company’s filings submitted to BSE.

Shilpa Medicare Share Price

812.25 -9.65 (-1.17%)
17-Aug-2026 12:45 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1904.00
Dr. Reddys Labs. 1190.85
Cipla 1428.35
Lupin 2224.75
Zydus Lifesciences 1141.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: